OPTIMA: A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Background: Multi-parameter gene expression assays (MPAs) are widely used to estimate individual patient residual risk in hormone-sensitive HER2-negative node-negative early breast cancer, allowing patients with low risk to safely avoid chemotherapy. Evidence for MPA use in node-positive breast cancer is limited. OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis) aims to validate MPA’s as predictors of chemotherapy sensitivity in a largely node-positive breast cancer population.
Description
Keywords
Journal Title
CANCER RESEARCH
Conference Name
SABCS 2017
Journal ISSN
0008-5472
1538-7445
1538-7445
Volume Title
78